Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome update in the medical world. Abbott Vascular Inc., CARDIONOVUM GmbH, Elixir Medical Corporation, HangZhou HuaAn Biotechnology Co.,Ltd, IRAMED GmbH Company, Medinol Ltd. Company, OrbusNeich Company, REVA Medical, Inc., Stentys, SA Company, Tepha, Inc. Company, Tryton Medical, Inc., VasoTech Inc., Xenogenics Corporation and Zorion Medical Company are some of the leading manufacturers and suppliers of drug eluting stents. Each of the providers also run a clinical trial for bettering the product. Abbott has come up with new technology called XIENCE Xpedition. It makes the process of complex coronary operation easy and hassle free.
Many new forms of treatment are being uncovered through clinical trials and the manufacturing companies are investing heavily in its R&D. Experts consider that price will pay an important role in this selection of Drug Eluting Stents over bare-metal stents. As Drug Eluting Stents are expensive many might not be able to afford the same. These stents used are biodegradable polymer that significantly improves the process of operation. As superior quality products are used without any other alternative the prices for the stents are very high. The need of the hour is to explain the benefits of Drug Eluting Stents to the end-users such that they select it over other alternatives. Germany has been one of the first nations to have adopted Drug Eluting Stents. 80% of coronary operations done in America as based on this technology. Other prospective markets can be Spain & Portugal.
In order to explore this market further one can refer to the Drug Eluting Stents (DES) – Pipeline Review, 2015@ http://www.rnrmarketresearch.com/drug-eluting-stents-des-pipeline-review-2015-market-report.html